This is the authors' abstract. We don't add key points for this paper.
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal carcinoma. These NCCN Guidelines Insights highlight the recent updates/changes in these guidelines, and updates include axitinib as first-line treatment option for patients with clear cell renal carcinoma, new data to support pazopanib as subsequent therapy for patients with clear cell carcinoma after first-line treatment with another tyrosine kinase inhibitor, and guidelines for follow-up of patients with renal cell carcinoma.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Motzer et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: